Form 4: Foghorn Therapeutics Director Acquires Stock Options

Thomas J. Lynch Jr., a Director at Foghorn Therapeutics Inc., has acquired stock options granting the right to purchase 28,000 shares.

Summary

• Thomas J. Lynch Jr., a Director at Foghorn Therapeutics Inc. (FHTX), has been granted stock options.
• The options provide the right to purchase 28,000 shares of common stock.
• The exercise price for these options is $4.08 per share.
• The earliest transaction date associated with this filing is June 24, 2026.
• The options vest in full on the first anniversary of the grant date, contingent on continued service as a director.
• A power of attorney was executed on December 1, 2025, authorizing Michael LaCascia, Adrian Gottschalk, and Samantha Macina to act on behalf of Tom Lynch for SEC filings.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it reports a standard stock option grant to a director rather than significant financial results or strategic shifts.

Positives

• Director acquisition of stock options indicates potential alignment of management interests with shareholder value.
• The option grant suggests confidence in the company's future prospects by a key insider.

Risks

• The vesting condition tied to continued service means the options could be forfeited if the reporting person leaves the board.
• The value of the options is subject to the future performance of Foghorn Therapeutics' stock price.

Future Outlook

The filing does not contain forward-looking statements or guidance regarding future financial performance. It solely reports a transaction related to stock options.

Management Comments

• The option vests in full on the first anniversary of the grant date, subject to the reporting person's continued service on the board of directors.

Industry Context

StockSavvy.ai notes that the grant of stock options to a director is a common practice in the biotechnology and pharmaceutical sectors, aligning executive incentives with long-term company growth and value creation.

Corporate Governance

Stakeholder Impact

• Shareholders: The option grant may be viewed positively as it aligns director incentives with company performance, potentially leading to increased shareholder value if the stock price rises.
• Employees: Indirectly, the alignment of director incentives can contribute to overall company stability and growth, benefiting employees.

Next Steps

• The stock options will vest on the first anniversary of the grant date, provided Thomas J. Lynch Jr. continues to serve as a director.
• Thomas J. Lynch Jr. may exercise these options at the specified price of $4.08 per share after they vest.

Key Dates

Keywords

Foghorn Therapeutics, FHTX, Form 4, Stock Options, Director, Insider Trading, SEC Filing, Beneficial Ownership